hypothalamic-pituitary-adrenal axis | News Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

10,983 results for “hypothalamic-pituitary-adrenal axis”

HMNC Brain Health and Spruce Biosciences Launch Phase 2 Trial for Precision Depression Treatment

Plastic Chemical DEHP Rewires Fetal Brain Anxiety Circuits via GABA, Study Shows

FDA Grants Rare Pediatric Disease Designation to 101-PGC-005 for Systemic Juvenile Idiopathic Arthritis

Seaport Therapeutics Initiates Phase 2b Trial of Novel Oral Antidepressant GlyphAllo

Repeated High-Voltage Pulsed Radiofrequency Reduces Postherpetic Neuralgia Incidence in Diabetic Patients with Thoracic Herpes Zoster

Seven Real-World Studies Demonstrate NEFECON's Efficacy in IgA Nephropathy Treatment Across Diverse Patient Populations

STAR Trial Demonstrates Trauma-Focused CBT Is Safe and Effective for PTSD in Patients with Psychosis, Challenging Decades of Clinical Exclusion

Psychedelic Therapies Advance Through Clinical Trials as HMNC's Novel Ketamine Formulation Shows Promise

Luye Pharma Initiates Phase 1 Trial for Novel Triple-Target Antidepressant LY03021

Gut Microbial Metabolites May Shape Vulnerability to Stress-Related Mental Disorders, Review Finds

Page 1 of 73